Drugs / Anti-CD22 CAR NK Cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT03692767 | Mar 2019 → Nov 2020 | B-cell non-Hodgkin lymphoma | Allife Medical Science and Technology Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anti-CD22 CAR NK Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03692767 ↗ |
| Modality | Cell therapy | “Anti-CD22 CAR NK cells” NCT03692767 ↗ |
| Target | CD22 | “Anti-CD22” NCT03692767 ↗ |